Epizyme Inc., of Cambridge, Mass., closed its public offering of 9.6 million shares at $9 per share, which included 1.25 million shares issued through the underwriter's option, grossing the company $86.25 million. The company plans to use the proceeds to fund development and commercialization costs of tazemetostat outside of Japan, as well as for its other pipeline candidates, including EZM-8266, and for working capital and other general corporate purposes. Jefferies acted as book-running manager for the offering.